Literature DB >> 8223447

Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif.

M Zanetti1, G Filaci, R H Lee, P del Guercio, F Rossi, R Bacchetta, F Stevenson, V Barnaba, R Billetta.   

Abstract

We report that an antibody engineered to express three Arg-Gly-Asp (RGD) repeats in the third complementarity-determining region of the heavy chain (antigenized antibody) efficiently inhibits the lysis of human erythroleukemia K-562 cells by natural killer (NK) cells. Synthetic peptides containing RGD did not inhibit. Inhibition was specific for the (RGD)3-containing loop and required simultaneous occupancy of the Fc receptor (CD16) on effector cells. The antigenized antibody inhibited other forms of cytotoxicity mediated by NK cells but not cytotoxicity mediated by major histocompatibility complex-restricted cytotoxic T lymphocytes (CTL). A three-dimensional model of the engineered antibody loop shows the structure and physicochemical characteristics probably required for the ligand activity. The results indicate that an RGD motif is involved in the productive interaction between NK and target cells. Moreover, they show that peptide expression in the hypervariable loops of an antibody molecule is an efficient procedure for stabilizing oligopeptides within a limited spectrum of tertiary structures. This is a new approach towards imparting ligand properties to antibody molecules and can be used to study the biological function and specificity of short peptide motifs, including those involved in cell adhesion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223447      PMCID: PMC413734          DOI: 10.1002/j.1460-2075.1993.tb06122.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  75 in total

1.  The three-dimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions.

Authors:  A L Main; T S Harvey; M Baron; J Boyd; I D Campbell
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

2.  Crystal structure of an HIV-binding recombinant fragment of human CD4.

Authors:  S E Ryu; P D Kwong; A Truneh; T G Porter; J Arthos; M Rosenberg; X P Dai; N H Xuong; R Axel; R W Sweet
Journal:  Nature       Date:  1990-11-29       Impact factor: 49.962

Review 3.  Biology and clinical relevance of human natural killer cells.

Authors:  M J Robertson; J Ritz
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

Review 4.  Natural killer cells.

Authors:  L L Lanier; J H Phillips
Journal:  Curr Opin Immunol       Date:  1992-02       Impact factor: 7.486

5.  Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains.

Authors:  J H Wang; Y W Yan; T P Garrett; J H Liu; D W Rodgers; R L Garlick; G E Tarr; Y Husain; E L Reinherz; S C Harrison
Journal:  Nature       Date:  1990-11-29       Impact factor: 49.962

6.  Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice.

Authors:  M Bix; N S Liao; M Zijlstra; J Loring; R Jaenisch; D Raulet
Journal:  Nature       Date:  1991-01-24       Impact factor: 49.962

7.  Participation of CD11a-c/CD18, CD2 and RGD-binding receptors in endogenous and interleukin-2-stimulated NK activity of CD3-negative large granular lymphocytes.

Authors:  T Timonen; C G Gahmberg; M Patarroyo
Journal:  Int J Cancer       Date:  1990-12-15       Impact factor: 7.396

8.  Preservation of lymphokine-activated killer activity following T cell depletion of human bone marrow.

Authors:  W R Drobyski; V Piaskowski; R C Ash; J T Casper; R L Truitt
Journal:  Transplantation       Date:  1990-10       Impact factor: 4.939

9.  Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis.

Authors:  M J Robertson; M A Caligiuri; T J Manley; H Levine; J Ritz
Journal:  J Immunol       Date:  1990-11-15       Impact factor: 5.422

10.  Structure of a fibronectin type III domain from tenascin phased by MAD analysis of the selenomethionyl protein.

Authors:  D J Leahy; W A Hendrickson; I Aukhil; H P Erickson
Journal:  Science       Date:  1992-11-06       Impact factor: 47.728

View more
  7 in total

1.  Proteolytic excision and in situ cyclization of a bioactive loop from an REI-VL presentation scaffold.

Authors:  L R Helms; R Wetzel
Journal:  Protein Sci       Date:  1994-07       Impact factor: 6.725

2.  Cytotoxic T cell immunity against telomerase reverse transcriptase in humans.

Authors:  B Minev; J Hipp; H Firat; J D Schmidt; P Langlade-Demoyen; M Zanetti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

3.  Forced unfolding of the fibronectin type III module reveals a tensile molecular recognition switch.

Authors:  A Krammer; H Lu; B Isralewitz; K Schulten; V Vogel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

4.  Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors.

Authors:  S Valsesia-Wittmann; A Drynda; G Deléage; M Aumailley; J M Heard; O Danos; G Verdier; F L Cosset
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

5.  The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6.

Authors:  F Martin; C Toniatti; A L Salvati; S Venturini; G Ciliberto; R Cortese; M Sollazzo
Journal:  EMBO J       Date:  1994-11-15       Impact factor: 11.598

6.  Peptide Inhibition of Topoisomerase IB from Plasmodium falciparum.

Authors:  Amit Roy; Ilda D'Annessa; Christine J F Nielsen; David Tordrup; Rune R Laursen; Birgitta Ruth Knudsen; Alessandro Desideri; Felicie Faucon Andersen
Journal:  Mol Biol Int       Date:  2011-05-04

7.  A monoclonal antibody that inhibits mycobacterial DNA gyrase by a novel mechanism.

Authors:  Ujjini H Manjunatha; Anthony Maxwell; Valakunja Nagaraja
Journal:  Nucleic Acids Res       Date:  2005-06-01       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.